Unresolved questions for nutrient-stimulated hormonal multi-agonists in MASH; more receptors, better livers?: Editorial on “Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders”
Clinical and Molecular Hepatology · 01.10.2026 · 32 (4) · e2026.1064
DOI: 10.3350/cmh.2026.1064 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2026. Verfasst von Dae Won Jun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. noshin@hanyang.ac.kr. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
In this issue of Clinical and Molecular Hepatology, Cho and Jung provide a comprehensive account of the evolution of nutrient-stimulated hormonal (NUSH) multi-agonists, tracing the field from the discovery of the incretin effect to the triple agonists and non-peptidyl oral agents now entering late-phase development.1 Their review frames the NUSH system-glucagon-like peptide-1 (GLP-1), glucosedependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY-as a set of hormones acting on spatially distinct yet functionally integrated receptors across the pancreas, brain, gastrointestinal tract, liver, and adipose tissue.Importantly, the authors do not treat multi-agonism merely as a route to more potent weight loss.Rather, their review provides a framework that invites a more fundamental question: whether engaging additional receptors will necessarily translate into better hepatic outcomes.Read from a hepatological standpoint, that question deserves to be posed more sharply still.Alongside the striking success of GLP-1 receptor agonists in obesity, hepatologists confront a more sobering pattern.In the phase 2 SYNERGY-NASH trial, tirzepatide 15 mg achieved metabolic dysfunction-associated steatohepatitis (MASH) resolution without worsening of fibrosis in Unresolved questions for nutrient-stimulated hormonal multi-agonists in MASH; more receptors, better livers?: Editorial on "Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders"
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. noshin@hanyang.ac.kr.
- Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. drwon1@snu.ac.kr.
Zitieren
APA
Jun, D. W., & Kim, W. (2026). Unresolved questions for nutrient-stimulated hormonal multi-agonists in MASH; more receptors, better livers?: Editorial on “Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders”. Clinical and Molecular Hepatology, 32(4), e2026.1064. https://doi.org/10.3350/cmh.2026.1064
Vancouver
Jun DW, Kim W. Unresolved questions for nutrient-stimulated hormonal multi-agonists in MASH; more receptors, better livers?: Editorial on “Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders”. Clinical and Molecular Hepatology. 2026;32(4):e2026.1064. doi:10.3350/cmh.2026.1064
BibTeX
@article{Jun2026,
author = {Jun, Dae Won and Kim, Won},
title = {Unresolved questions for nutrient-stimulated hormonal multi-agonists in MASH; more receptors, better livers?: Editorial on “Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders”},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {4},
pages = {e2026.1064},
doi = {10.3350/cmh.2026.1064}
}
EUVIMED